Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | Rap guanine nucleotide exchange factor (GEF) 4 | Starlite/ChEMBL | No references |
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Equus caballus | Ferritin light chain | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Onchocerca volvulus | Rap guanine nucleotide exchange factor 1 homolog | Get druggable targets OG5_131726 | All targets in OG5_131726 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_131726 | All targets in OG5_131726 |
Brugia malayi | N-terminal motif family protein | Get druggable targets OG5_131726 | All targets in OG5_131726 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 43.9 % |
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Echinococcus multilocularis | expressed protein | Ferritin light chain | 175 aa | 146 aa | 30.1 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 142 aa | 29.6 % |
Schistosoma japonicum | Ferritin, putative | Ferritin light chain | 175 aa | 144 aa | 24.3 % |
Echinococcus granulosus | expressed protein | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 44.4 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | carnitine/choline acetyltransferase, putative | 0.0047 | 0.0721 | 0.0984 |
Trypanosoma cruzi | choline/carnitine O-acyltransferase, putative | 0.0047 | 0.0721 | 0.0984 |
Brugia malayi | hypothetical protein | 0.0146 | 0.2968 | 0.2968 |
Brugia malayi | Choline O-acetyltransferase | 0.0047 | 0.0721 | 0.0721 |
Leishmania major | carnitine/choline acetyltransferase, putative | 0.0047 | 0.0721 | 0.0984 |
Loa Loa (eye worm) | carnitine O-palmitoyltransferase I isoform | 0.0047 | 0.0721 | 0.0534 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0047 | 0.0721 | 0.0984 |
Trypanosoma cruzi | carnitine/choline acetyltransferase, putative | 0.0047 | 0.0721 | 0.0984 |
Onchocerca volvulus | Rap guanine nucleotide exchange factor 1 homolog | 0.0218 | 0.4594 | 1 |
Schistosoma mansoni | choline o-acyltransferase | 0.0047 | 0.0721 | 0.5 |
Trypanosoma brucei | carnitine O-palmitoyltransferase, putative | 0.0047 | 0.0721 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0146 | 0.2968 | 0.2827 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0024 | 0.0197 | 0.5 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0047 | 0.0721 | 1 |
Loa Loa (eye worm) | choline/Carnitine O-acyltransferase | 0.0047 | 0.0721 | 0.0534 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0047 | 0.0721 | 0.0984 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0047 | 0.0721 | 0.0984 |
Trypanosoma cruzi | choline/carnitine O-acyltransferase, putative | 0.0259 | 0.5524 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0047 | 0.0721 | 0.0984 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0047 | 0.0721 | 0.0984 |
Loa Loa (eye worm) | choline O-acetyltransferase | 0.0047 | 0.0721 | 0.0534 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0024 | 0.0197 | 0.5 |
Leishmania major | carnitine palmitoyltransferase-like protein | 0.0047 | 0.0721 | 0.0984 |
Brugia malayi | hypothetical protein | 0.0024 | 0.0197 | 0.0197 |
Loa Loa (eye worm) | hypothetical protein | 0.0047 | 0.0721 | 0.0534 |
Trypanosoma brucei | carnitine O-acetyltransferase, putative | 0.0047 | 0.0721 | 1 |
Trypanosoma cruzi | carnitine O-palmitoyltransferase II, putative | 0.0047 | 0.0721 | 0.0984 |
Loa Loa (eye worm) | hypothetical protein | 0.0456 | 1 | 1 |
Brugia malayi | Choline O-acetyltransferase | 0.0047 | 0.0721 | 0.0721 |
Onchocerca volvulus | 0.0146 | 0.2968 | 0.5801 | |
Trypanosoma brucei | carnitine O-palmitoyltransferase II, putative | 0.0047 | 0.0721 | 1 |
Trypanosoma cruzi | carnitine O-acetyltransferase, putative | 0.0047 | 0.0721 | 0.0984 |
Trypanosoma cruzi | choline/carnitine O-acetyltransferase, putative | 0.0047 | 0.0721 | 0.0984 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0024 | 0.0197 | 0.5 |
Trypanosoma cruzi | choline/carnitine O-acyltransferase, putative | 0.0259 | 0.5524 | 1 |
Schistosoma mansoni | choline o-acyltransferase | 0.0047 | 0.0721 | 0.5 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0024 | 0.0197 | 0.5 |
Trypanosoma brucei | carnitine O-palmitoyltransferase II, putative | 0.0047 | 0.0721 | 1 |
Brugia malayi | Choline/Carnitine o-acyltransferase family protein | 0.0047 | 0.0721 | 0.0721 |
Loa Loa (eye worm) | hypothetical protein | 0.0218 | 0.4594 | 0.4486 |
Brugia malayi | Choline/Carnitine o-acyltransferase family protein | 0.0047 | 0.0721 | 0.0721 |
Brugia malayi | N-terminal motif family protein | 0.0218 | 0.4594 | 0.4594 |
Echinococcus multilocularis | carnitine O palmitoyltransferase 1, liver | 0.0259 | 0.5524 | 1 |
Echinococcus granulosus | carnitine O palmitoyltransferase 1 liver | 0.0259 | 0.5524 | 1 |
Leishmania major | choline/Carnitine o-acyltransferase-like protein | 0.0259 | 0.5524 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | > 53 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of uHTS hits for small molecule agonists of the CRF-binding protein and CRF-R2 receptor complex. (Class of assay: confirmatory) | ChEMBL. | No reference |
IC50 (functional) | > 47.1 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of uHTS hits for small molecule antagonists of the CRF-binding protein and CRF-R2 receptor complex. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.4125 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 2.0787 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 7.0795 uM | PubChem BioAssay. qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 19.9526 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.